Sturz- und Frakturrisiko von Menschen mit Thalidomid-Embryopathie

Abstract

Background

The experience of medical competence centres for people with thalidomide embryopathy suggests that fall-related injuries are relatively common. As falls in old age favour morbidity and loss of autonomy, fall and fracture risks in people with thalidomide embryopathy were investigated.

Methods

Online survey (Survey Monkey) on functional limitations and fall events of persons with thalidomide embryopathy (TE group) and nonaffected persons (control group).

Results

206 people in the TE group and 183 in the control group were surveyed. Hearing, balance, vision, sensitivity and strength impairments were significantly more common in the TE group than in the control group. People in the TE group reported falls and injuries significantly more frequently than those in the control group.

Conclusion

People with thalidomide embryopathy have more frequent falls with more serious injuries than those not affected. The results of the present study reinforce the necessity of individual risk assessment and the implementation of preventive measures aimed at preventing falls in this patient group.

Schlüsselwörter

Sturzrisiken - Verletzungen - Behinderungen - Ältere - Thalidomid-Embryopathie

Publication History

Received: 25 June 2024

Accepted after revision: 13 August 2025

Article published online:
22 September 2025

• Literatur/References

• 1 Becker C, Rapp K. Stürze in der Geriatrie. Diagnostik und Therapie. Internist 2011; 52: 939-945
• 2 Saß AC, Varnaccia G, Rommel A. Robert Koch-Institut. Sturzunfälle in Deutschland. Faktenblatt zu GEDA 2010: Ergebnisse der Studie „Gesundheit in Deutschland aktuell 2010“ RKI. 2016 Accessed September 05, 2025 at: https://edoc.rki.de/bitstream/handle/176904/3064/Sturzunf%c3%a4lle.pdf?sequence=1&isAllowed=y
• 3 Schoene D, Kiesswetter E, Sieber CC. et al. Skelettmuskuläre Faktoren, Sarkopenie und Stürze im Alter. Z Gerontol Geriatr 2019; 52: 37-44
• 4 Bundesministerium für Gesundheit. Pflege- und Unterstützungsbedarf sogenannter vulnerabler Gruppen. 2018 Accessed September 10, 2024 at: https://www.bundesgesundheitsministerium.de/fileadmin/Dateien/5_Publikationen/Pflege/Berichte/Vulnerable_Gruppen_Schlussbericht_FINAL_2018_05_17.pdf
• 5 Peters KM, Albus C, Lüngen M. et al. Gesundheitsschäden, psychosoziale Beeinträchtigungen und Versorgungsbedarf von contergangeschädigten Menschen aus Nordrhein-Westfalen in der Langzeitperspektive. Gutachten im Auftrag des LZG.NRW. 2016 Accessed September 10, 2024 at: https://www.lzg.nrw.de/_php/login/dl.php?u=/_media/pdf/service/Pub/2015_df/LZG_NRW_Gutachten_Contergan_Abschlussbericht_ue_2016.pdf
• 6 Niethardt FU, Marquardt E, Eltze J. , ed. Contergan. 30 Jahre danach. Stuttgart: Ferdinand Enke; 1994
• 7 Binkley JM, Stratford PW, Lott SA. et al. The Lower Extremity Functional Scale (LEFS). Scale development, measurement properties, and clinical application. North American Orthopaedic Rehabilitation Research Network. Phys Ther 1999; 79: 371-383
• 8 Naal FD, Impellizzeri FM, Torka S. et al. The German Lower Extremity Functional Scale (LEFS) is reliable, valid and responsive in patients undergoing hip or knee replacement. Qual Life Res 2015; 24: 405-410
• 9 Cohen J. A power primer. Psychol Bull 1992; 112: 155-159
• 10 Clopper CJ, Pearson ES. The Use of Confidence or Fiducial Limits Illustrated in the Case of the Binomial. Biometrika 1934; 26: 404
• 11 Hinoshita F, Beppu H, Shioji S. et al. A nationwide survey regarding the life situations of patients with thalidomide embryopathy in Japan, 2018. First report. Birth Defects Res 2019; 111: 1633-1642
• 12 Imai K, Sone H, Otomo K. et al. Quality of life and pain in patients with thalidomide embryopathy in Japan. Mol Genet Genomic Med 2020; 8: e1464
• 13 Vargesson N, Hooper G, Giddins G. et al. Thalidomide upper limb embryopathy – pathogenesis, past and present management and future considerations. J Hand Surg Eur Vol 2023; 48: 699-709
• 14 Markiewicz M, Stirling P, Brennan S. et al. Age-related changes in patients with upper limb thalidomide embryopathy in the United Kingdom. J Hand Surg Eur Vol 2023; 48: 773-780
• 15 Newbronner E, Glendinning C, Atkin K. et al. The health and quality of life of Thalidomide survivors as they age – Evidence from a UK survey. PLoS One 2019; 14: e0210222
• 16 Shiga T, Shimbo T, Yoshizawa A. Multicenter investigation of lifestyle-related diseases and visceral disorders in thalidomide embryopathy at around 50 years of age. Birth Defects Res A Clin Mol Teratol 2015; 103: 787-793
• 17 Beyer R, Peters KM, Schulte-Hillen J. et al. Nationales Kompetenznetzwerk Contergan – Sicherstellung der medizinischen Versorgung von Menschen mit Thalidomid-Embryopathie. Dtsch Med Wochenschr 2022; 147: 1281-1285
• 18 Morrison D. Poor balance, bilateral upper limb phocomelia, no previous exercise. A challenging combination for fall prevention in a middle-aged thalidomide survivor. BMJ Case Rep 2020; 13
• 19 Balzer K, Bremer M, Schramm S. Deutsches Institut für Medizinische Dokumentation und Information (DIMDI). et al. Sturzprophylaxe bei älteren Menschen in ihrer persönlichen Wohnumgebung. Health Technology Assessment 2012; 116